MRK

MRK is a health care company that makes prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, including a new pill aimed at cutting cholesterol. Its first-quarter fiscal 2026 earnings report showed revenue of $16.29 billion (a 4.9% year-over-year gain), sales of cancer treatment Keytruda hitting $8.0 billion (an 8% rise), and increased annual revenue and per-share earnings guidance to $67 billion and $5.15, respectively. The company reports again on Aug. 4. No wonder MRK shares are up 21% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock. Institutional volumes reveal plenty. In the last year, MRK has enjoyed strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in MRK shares. They reflect our proprietary inflow signal, pushing the stock higher: Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Merck. Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, MRK has had strong profits and earnings growth: Profit margin (+28.1%) 3-year EPS growth rate (+1,502.8%) Source: FactSet Also, EPS is estimated to ramp higher this year by +244.7%. Now it makes sense why the stock has been generating Big Money interest. MRK has a track record of strong financial performance. Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term. Merck has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis. MRK produced 122 rare Outlier 20 inflow signals since 1990, gaining 3,453% in that time. The blue bars below show when the stock was a top pick…institutions have been fans for a long time: Tracking unusual volumes reveals the power of money flows. This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward. The MRK action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio. Disclosure: the au...

Pfizer PFE is one of the world’s leading oncology drugmakers, with a strong presence across breast, genitourinary, thoracic, gastrointestinal and hematologic cancers. The company has built a broad portfolio of marketed cancer therapies and maintains a deep oncology pipeline spanning multiple treatment modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 7% to $3.8 billion in the first quarter of 2026. Investors will be keen to know how its oncology segment performed in the second quarter when the company announces results on Aug. 4. Pfizer’s oncology sales in the second quarter are expected to have been driven by higher sales of key drugs like Padcev, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance and Adcetris. Sales of the new drug, Elrexfio, are also likely to have risen in the quarter. The Zacks Consensus Estimate for Padcev is $661 million, while that for Ibrance is $1.05 billion. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Its oncology biosimilars are expected to have made a significant contribution to sales growth in the second quarter of 2026, similar to the past few quarters. Pfizer is also likely to provide updates on its key oncology candidates on the second-quarter conference call. Several oncology candidates have entered late-stage development, such as atirmociclib and sigvotatug vedotin. A regulatory application seeking approval of sasanlimab is also under review in the EU. Last year, Pfizer entered into a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to PF-08634404, a dual PD-1 and VEGF inhibitor, which it plans to establish as a potential backbone therapy across multiple tumor types. Pfizer plans to start four pivotal studies for PF-08634404 in 2026. An update on PF-08634404 is expected on the second-quarter conference call. Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca AZN, Merck MRK, J&J JNJ and Bristol-Myers. For J&J, the Oncology segment comprises around 29% of total revenues and 45% of its Innovative Medicine segment sales. Its oncology sales rose 17.8% on an operational basis in the first...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health pharmaceuticals across various areas, including Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, and other brands. Valued at a market cap of $306.3 billion, the company also provides veterinary pharmaceuticals, vaccines and health management solutions and services. MRK is expected to release its Q2 2026 earnings on Tuesday, Aug. 4, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.36 on a diluted basis, down 36.2% from $2.13 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters. Dear Google Stock Fans, Mark Your Calendars for July 13 Oracle Stock Crashes to a 52-Week Low. Here’s Why It Might Be Time to Buy. Costco vs. Walmart: 1 Dividend-Paying Retail Giant Stands Above the Other Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2026, analysts project the company’s EPS to be $4.35, down 51.6% from $8.98 in fiscal 2025. However, its EPS is expected to rise by roughly 127.6% year over year (YoY) to $9.90 in fiscal 2027. MRK stock has grown 48.8% over the past 52 weeks, rallying the S&P 500 Index’s ($SPX) 20.1% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 19.4% rise during the same time frame. On Apr. 8, MRK stock rose 3.3% following the announcement of the company’s cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (TERN), a clinical-stage oncology company, following the announcement of its definitive agreement to acquire Terns, which happened last month. The transaction was for $53 per share in cash, with an approximate equity value of $6.7 billion. This acquisition expands MRK’s presence in hematology with TERN-701 and further diversifies and strengthens its position in oncology solutions. Analysts are somewhat optimistic about MRK, with the stock having a “Moderate Buy” rating overall. Among the 28 analysts covering the stock, 16 are recommending a “Strong Buy,” two suggest a “Moderate Buy,” and 10 suggest a “Hold.” MRK’s average analyst price target is $133.89, indicating an upside of 7.9% from the...

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growt

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

RAHWAY, N.J., July 01, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic facto...

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 ISLEND-1 and ISLEND-2 studies of weekly islatravir/lenacapavir for HIV medication. Additionally, the companies reported negative findings from the EVOKE-03 study comparing Trodelvy with Keytruda versus Keytruda monotherapy in patients with first-line PD-L1 non-small cell lung cancer. Moreover, on June 8, RBC Capital reaffirmed its $122 Sector Perform rating for Gilead Sciences Inc. (NASDAQ:GILD). The firm made remarks regarding the company’s position in the domain of in vivo CAR-T treatment. The firm added that in vivo CAR-T represents a possible risk to a sector that is estimated to account for 10-15% of Gilead’s potential revenue. According to RBC Capital, Gilead Sciences Inc. (NASDAQ:GILD) has begun to build promising technology in the field with differentiating features and a wide approach that incorporates current experience. Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.

The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas

NEW YORK, June 25, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective. For additional information, please visit www.lseg.com. Unlock Your Growth Potential with AlgerFounded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a suite of growth equity separate accounts, mutual funds, ETFs, and privately offered investment vehicles. Alger's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for more than 60 years. For more information, please visit www.alger.com. Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. Alger pays compensation to third party marketers to sell various strategies to prospective investors. London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" "Russell®", "FTSE Russell®" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. View original content to download multimedia:https://www.prnewswire.com/news...

US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).

NEW YORK, June 22, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective. For additional information, please visit www.lseg.com. Unlock Your Growth Potential with Alger Founded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a suite of growth equity separate accounts, mutual funds, ETFs, and privately offered investment vehicles. Alger's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for more than 60 years. For more information, please visit www.alger.com. Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. Alger pays compensation to third party marketers to sell various strategies to prospective investors. London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" "Russell®", "FTSE Russell®" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. View original content to download multimedia:https://www.prnewswire.com/new...

First-in-class anti-CD155 antibody demonstrated favorable safety profile and preliminary anti-tumor activity across multiple difficult-to-treat cancer types JERUSALEM, June 17, 2026 /PRNewswire/ -- Nectin Therapeutics, a clinical-stage oncology company developing first-in-class immuno-oncology and antibody-drug conjugate (ADC) therapies, today announced the presentation of Phase 1a/1b clinical data of NTX1088 in combination with pembrolizumab (Keytruda®), Merck's (known as MSD outside of the U.S. and Canada) anti-PD1 therapy, during an oral presentation at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The data highlighted NTX1088, a first-in-class monoclonal antibody targeting the poliovirus receptor (PVR; CD155), a key regulator of the DNAM1 axis and an important driver of tumor-mediated immune suppression. The results were presented from the ongoing Phase 1a/1b, open-label, multicenter, dose-escalation and expansion study, NTX-1088-01 (KEYNOTE E92, NCT05378425), evaluating NTX1088 as both a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. A total of 91 patients were treated in the study., and NTX1088 was well tolerated, with no dose-limiting toxicities observed. Based on pharmacokinetics and target occupancy, a dose of 1,750 mg was selected as the recommended dose for expansion. Preliminary efficacy analysis focused on patients receiving active dose levels of NTX1088 (1200 and 1750 mg) in combination with pembrolizumab (200 mg). Among 41 evaluable patients, confirmed partial responses (PRs) were observed across multiple tumor types, including gastric, bladder, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and melanoma. The study population represented a particularly challenging treatment setting, with a median of four prior lines of therapy and high rates of prior immune checkpoint inhibitors (CPIs) exposure. Additional patients achieved stable disease, and most responding patients were ongoing at data cutoff with a maximum treatment duration of 24 months. "These Phase 1 results indicate that NTX1088 in combination with pembrolizumab was well tolerated and demonstrated encouraging preliminary anti-tumor activity in a difficult-to-treat, CPI-pretreated population," said Sarina A. Piha-Paul, M.D., lead Principal Investigator of the NTX-1088-01 study...